Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 10:20 PM ET

Pharmaceuticals

Company Overview of Urigen Pharmaceuticals, Inc.

Company Overview

Urigen Pharmaceuticals, Inc. develops products to ameliorate the cause and symptoms associated with urological ailments. Its products include URG101, a proprietary combination therapy product that has completed a Phase II double blinded, placebo controlled, and multi-center trial for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS); and URG501, an oral pentosan polysulfate sodium therapy, which is in pre-clinical stage for the treatment of IC/BPS. The company is based in North Brunswick, New Jersey.

Technology Center of New Jersey

675 Highway One B-206

North Brunswick, NJ 08902

United States

Phone:

732-640-0160

Key Executives for Urigen Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 62
Scientific Founder, Chief Medical Officer, Director and Member of Scientific Advisory Board
Age: 69
Co-Founder and IP Counsel
Chief Financial Officer
Age: 62
Vice President of Finance & Operations and Director
Age: 29
Compensation as of Fiscal Year 2015.

Urigen Pharmaceuticals, Inc. Key Developments

Imprimis Pharmaceuticals, Inc. Enters into License Agreement with Urigen Pharmaceuticals, Inc. for Patented Urology Formulation

Imprimis Pharmaceuticals, Inc. announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Under the terms of the agreement, Imprimis shall pay Urigen tiered royalties based on net product sales with a minimum annual payment per unit for each prescription dispensed. The license does not require any cash payment by Imprimis upon execution. The license is non-exclusive for a period of six months, at which time Imprimis has the sole right to convert to an exclusive license. Once converted to an exclusive license, Imprimis is obligated to make certain annual minimum payments. The license is for the US market only and covers certain US patent rights that extend through 2026. The agreement contains provisions for the parties to remain long-term partners throughout the product lifecycle.

Similar Private Companies By Industry

Company Name Region
PharmPro Services United States
Liptis Pharmaceuticals USA, Inc. United States
HealthCare Pharmaceuticals, Inc. United States
Neurovance, Inc. United States
Adia Nutrition Systems United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 1, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Urigen Pharmaceuticals, Inc., please visit www.urigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.